{"entity":{"id":"nct02210104","kind":"trial","name":"Autologous CD4+ NY-ESO-1-specific T cells with ipilimumab in NY-ESO-1-expressing tumours (MD Anderson phase 1, withdrawn)","aka":[],"tldr":"A planned MD Anderson trial of helper T cells against the NY-ESO-1 protein, given with the immunotherapy drug ipilimumab, for melanoma and sarcoma. It was withdrawn before anyone joined.","summary":"The registry describes a phase I study of autologous CD4+ NY-ESO-1-specific T cells with anti-CTLA-4 (ipilimumab) and cyclophosphamide for patients with NY-ESO-1-expressing tumours, listing melanoma and sarcoma as conditions (ClinicalTrials.gov NCT02210104). It was withdrawn with an actual enrolment of 0; the reason given is \"Issues with tetramer staining\" (ClinicalTrials.gov NCT02210104). Cassian Yee is listed as principal investigator; the record names NIH grant R01CA104711 (ClinicalTrials.gov NCT02210104).","status":"withdrawn","asOf":"2026-11-05","links":[{"label":"ClinicalTrials.gov NCT02210104","url":"https://clinicaltrials.gov/study/NCT02210104"}],"tags":["failure"],"related":[],"cancers":["melanoma","sarcoma"],"sections":[],"technologies":[],"targets":["ctag1b"],"drugs":["ipilimumab","cyclophosphamide"],"companies":[],"institutions":["md-anderson","nci"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"nct":"NCT02210104","phase":"1","setting":"NY-ESO-1-expressing melanoma or sarcoma: cyclophosphamide, autologous CD4+ NY-ESO-1-specific T cells and ipilimumab","sponsor":"M.D. Anderson Cancer Center, with the National Institutes of Health and the National Cancer Institute","result":"Withdrawn before enrolment (0 participants); registry reason: \"Issues with tetramer staining\".","started":"2016-12","startedType":"actual","enrolled":0,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02210104/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"target":[{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}